- Home
- PROP vs MGNX Comparison
PROP vs MGNX Comparison
Compare PROP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROP
- MGNX
- Stock Information
- Founded
- PROP 2001
- MGNX 2000
- Country
- PROP United States
- MGNX United States
- Employees
- PROP N/A
- MGNX N/A
- Industry
- PROP Investment Bankers/Brokers/Service
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- PROP Finance
- MGNX Health Care
- Exchange
- PROP Nasdaq
- MGNX Nasdaq
- Market Cap
- PROP 120.5M
- MGNX 99.7M
- IPO Year
- PROP N/A
- MGNX 2013
- Fundamental
- Price
- PROP $2.47
- MGNX $1.69
- Analyst Decision
- PROP Strong Buy
- MGNX Hold
- Analyst Count
- PROP 5
- MGNX 5
- Target Price
- PROP $8.50
- MGNX $3.25
- AVG Volume (30 Days)
- PROP 2.7M
- MGNX 572.9K
- Earning Date
- PROP 08-12-2025
- MGNX 08-14-2025
- Dividend Yield
- PROP N/A
- MGNX N/A
- EPS Growth
- PROP N/A
- MGNX N/A
- EPS
- PROP N/A
- MGNX N/A
- Revenue
- PROP $88,854,000.00
- MGNX $165,495,000.00
- Revenue This Year
- PROP $5,710.68
- MGNX N/A
- Revenue Next Year
- PROP $28.49
- MGNX N/A
- P/E Ratio
- PROP N/A
- MGNX N/A
- Revenue Growth
- PROP N/A
- MGNX 303.47
- 52 Week Low
- PROP $2.01
- MGNX $0.99
- 52 Week High
- PROP $12.30
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- PROP 38.82
- MGNX 57.53
- Support Level
- PROP $2.01
- MGNX $1.44
- Resistance Level
- PROP $2.83
- MGNX $1.67
- Average True Range (ATR)
- PROP 0.29
- MGNX 0.11
- MACD
- PROP -0.08
- MGNX -0.00
- Stochastic Oscillator
- PROP 26.44
- MGNX 91.23
About PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.